抑郁症合并代谢性疾病的共病机制及其治疗药物的研究进展

抑郁症是严重危害人类身心健康的常见病,随着"生物–心理–社会"的现代医学模式转变,发现其常与其他重大疾病如糖尿病、高血脂、心脏病、高血压等代谢综合征组分并存,合并疾病发病率高且预后不良,以及造成对家庭和社会的高负担,关于其发病机制和防治措施的研究方兴未艾。抑郁症和代谢性疾病的发病可能存在一定共病基础和因果关系,旨在重点探讨脂质代谢紊乱和血管内皮功能障碍在抑郁症合并代谢性疾病的病理发展和共病机制中的作用,同时归纳总结现有治疗药物对脂质代谢异常和内皮功能障碍的影响,为临床用药的优选及其共病患者的治疗方式提供综述基础。

Research Progress on co-morbid mechanism and therapeutic drugs of depression complicated with metabolic diseases

Depression is a common disease that seriously endangers the physical and mental health of human beings with the change of the "bio-psycho-social" modern medical model, and it is found that depression often coexists with other major diseases such as diabetes, hyperlipidemia, heart disease, hypertension, and other metabolic syndrome components. The research on its pathogenesis and prevention measures is in the ascendant because of its high incidence and poor prognosis, as well as the high burden on the family and society. There may be a certain co-morbid basis and causal relationship between depression and metabolic diseases. The purpose of this paper is to explore the role of lipid metabolism disorder and vascular endothelial dysfunction in the pathological development and co-morbid mechanism of depression complicated with metabolic diseases. At the same time, the effects of existing therapeutic drugs on abnormal lipid metabolism and endothelial dysfunction are summarized. The purpose of this study is to provide a summary basis for the optimization of clinical medication and the treatment of patients with co-morbidities.